Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
Nancy Haff, Caitlin Colling, James S. Yeh, Gauri Bhatkhande et al.
Journal
American Heart Journal
Topics
Diabetes Treatment and Management
article
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
Nancy Haff, Caitlin Colling, James S. Yeh, Gauri Bhatkhande, Ted Robertson, Katherine Crum, Junwei Yang, Kaitlin E. Hanken, Julie C. Lauffenburger, Wendy Wood, Mike Sung, Leigh H. Simmons, Daniel M. Horn, Niteesh K. Choudhry, Daniel Gaposchkin
article en
Abstract
No abstract available for this paper.
Publication Tag
American Heart JournalVol. 285
Institutions
University of North Carolina at Chapel Hill (US), University of Southern California (US), Brigham and Women's Hospital (US), Earth Island Institute (US), Massachusetts General Hospital (US), Ideas42 (US)
Funders
National Institute on Aging, NHLBI Division of Intramural Research